| Autor: |
Taji Heravi, A., Henn, A., Deuster, S., McLennan, S., Gloy, V., Mitter, V. R., Briel, M., Making Randomized Trials Affordable Group |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Taji Heravi, Ala; Henn, Anne; Deuster, Stefanie; McLennan, Stuart; Gloy, Viktoria; Mitter, Vera Ruth; Briel, Matthias (2022). Investigational medicinal products, related costs and hospital pharmacy services for investigator-initiated trials: A mixed-methods study. PLoS ONE, 17(3), e0264427. Public Library of Science 10.1371/journal.pone.0264427 |
| ISSN: |
1932-6203 |
| DOI: |
10.1371/journal.pone.0264427 |
| Popis: |
Background Conducting high quality investigator-initiated trials (IITs) is challenging and costly. The costs of investigational medicinal products (IMPs) in IITs and the role of hospital pharmacies in the planning of IITs are unclear. We conducted a mixed-methods study to compare planned and actual costs of IMPs in Swiss IITs, to examine potential reasons for differences, and to gather stakeholder views about hospital services for IITs. Methods We included all IITs with IMP services from the Basel hospital pharmacy invoiced between January 2014 and June 2020 (n = 24). We documented trial and IMP characteristics including planned and actual IMP costs. Our working definition for a substantial cost difference was that the actual IMP costs were more than 10% higher than the planned IMP costs in a trial. We conducted semi-structured interviews with investigators, clinical trials unit and hospital pharmacy staff, and qualitatively analyzed transcribed interviews. Results For 13 IITs we observed no differences between planned and actual costs of IMPs (median, 11’000 US$; interquartile range [IQR], 8’882–16’302 US$), but for 11 IITs we found cost increases from a median of 11’000 US$ (IQR, 8’922–36’166 US$) to a median over 28’000 US$ (IQR, 13’004–49’777 US$). All multicenter trials and 10 of 11 IITs with patients experienced substantial cost differences. From the interviews we identified four main themes: 1) Patient recruitment and organizational problems were identified as main reasons for cost differences, 2) higher actual IMP costs were bearable for most investigators, 3) IMP services for IITs were not a priority for the hospital pharmacy, and 4) closer collaboration between clinical trial unit and hospital pharmacy staff, and sufficient staff for IITs at the hospital pharmacy could improve IMP services. Conclusions Multicenter IITs enrolling patients are particularly at risk for higher IMP costs than planned. These trials are more difficult to plan and logistically challenging, which leads to delays and expiring IMP shelf-lives. IMP services of hospital pharmacies are important for IITs in Switzerland, but need to be further developed. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
